Compare Neurocrine Biosciences Inc (NBIX) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs OneSpan Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while OneSpan Inc trades at $16.12 (market cap $593.32M). The key difference: Neurocrine Biosciences Inc is far larger — about 26.6× OneSpan Inc's market cap, and OneSpan Inc pays a 3.23% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | OSPN | |
|---|---|---|
Market Cap | $15.77B | $593.32M |
Sector | Health | Technology |
52-Week High | $185.50 | $16.92 |
52-Week Low | $123.10 | $10.15 |
Enterprise Value | $15.78B | $562.40M |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
OneSpan (OSPN) trades at $16.1, down 3.59% on the day, with technical indicators showing a neutral trend and key support at $16. The stock exhibits strong fundamentals, including a P/E of 9.1, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights institutional interest, such as Deutsche Bank's new position, and the company's introduction of DigipassONE for authentication modernization.
The outlook for OSPN is positive, supported by solid financials and analyst consensus, but risks include competitive pressures and cash flow volatility. With a consensus price target of $17.00 and 66.67% buy ratings, the stock offers potential upside, though investors should monitor execution risks and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
